top of page

Topic

Neoadjuvant Immunotherapy

5 Podcasts • 6 Cases on BackTable

Hear how experienced physicians approach Neoadjuvant Immunotherapy on BackTable. Learn from podcasts, cases, and courses curated by physician content creators, covering patient selection, workup, and procedure technique. Get the BackTable app to follow this Topic and hear more of the conversations that matter to your practice.

Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Tumor Board

Episode # 59  •  12 May 2026

Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?

With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most likely to shape HCC care? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of hepatocellular carcinoma beyond established PD-1/CTLA-4 regimens.

More on Neoadjuvant Immunotherapy

Loading recent podcasts…

Tumor Board

Tumor Board # 59

May 11, 2026

with Dr. Jonathan Mizrahi, Dr. Lingling Du, Dr. Craig Lockhart

Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?

With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most...

ENT

ENT & Allergy # 247

Nov 10, 2025

with Dr. Mihir Patel, Dr. Siddharth Sheth, Dr. Jennifer Johnson, Dr. Adam Luginbuhl

Keynote-689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer

When treating head and neck cancer, how can you tell the difference between true disease progression and...

1,200+ listens

ENT

ENT & Allergy # 245

Oct 27, 2025

with Dr. Dylan Roden, Dr. Ravindra Uppaluri, Dr. Adam Luginbuhl

Understanding Keynote-689: Immunotherapy for Head & Neck Cancer

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using...

2,700+ listens

Tumor Board

Tumor Board # 43

Jan 12, 2026

with Dr. Jun Gong, Dr. Jonathan Mizrahi

ESMO Update: Trial Results & New Therapies in Colorectal Cancer

Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board...

Tumor Board

Tumor Board # 32

Oct 27, 2025

with Dr. Dylan Roden, Dr. Ravindra Uppaluri, Dr. Adam Luginbuhl

Understanding Keynote-689: Immunotherapy for Head & Neck Cancer

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using...

Tumor Board

Tumor Board Case

Oct 27, 2025

HNC: T2N3 Primary Low Volume Head & Neck Squamous Cell Carcinoma

with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl

Tumor Board

Tumor Board Case

Oct 27, 2025

HNC: T4N2bM0 High Volume Primary Locally Advanced Head & Neck Squamous Cell Carcinoma

with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl

ENT

ENT Case

Oct 27, 2025

HNC: T3N0 Anterior Larynx Cancer with Erosion of Thyroid Cartilage Inner Table

with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl

Tumor Board

Tumor Board Case

Oct 27, 2025

HNC: T3N0 Anterior Larynx Cancer with Erosion of Thyroid Cartilage Inner Table

with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl

ENT

ENT Case

Oct 27, 2025

HNC: T2N3 Primary Low Volume Head & Neck Squamous Cell Carcinoma

with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl

ENT

ENT Case

Oct 27, 2025

HNC: T4N2bM0 High Volume Primary Locally Advanced Head & Neck Squamous Cell Carcinoma

with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page